DOTmed January 17, 2025
Telix Pharmaceuticals has announced an agreement to acquire a pipeline of therapeutic assets and a biologics technology platform from California-based antibody engineering company ImaginAb.
The deal, valued at up to $230 million, includes early-stage drug candidates targeting DLL3 and integrin αvβ6, alongside other discovery-stage assets. These candidates are designed for cancer imaging and treatment using radiopharmaceuticals, particularly alpha emitters. ImaginAb’s technology uses small engineered antibody formats for precise tumor targeting and efficient blood clearance, which complements Telix’s current pipeline.
Telix, headquartered in Melbourne, develops therapeutic and diagnostic radiopharmaceuticals addressing oncology and rare diseases, with operations across the U.S., Europe, and Asia.
As part of the agreement, Telix...
Today's Sponsors
Today's Sponsor